[1]金其庄, 王玉柱, 叶朝阳, 等.中国血液透析用血管通路专家共识(第2版)[J]. [J].中国血液净化, 2019, 18(6):365-381
[2]Roy-Chaudhury P, Sukhatme VP, Cheung AK.Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint[J].J Am Soc Nephrol, 2006, 17(4):1112-1127
[3]Mima A.Hemodialysis Vascular Access Dysfunction: Molecular Mechanisms and Treatment[J].Ther Apher Dial, 2012, 16(4):321-327
[4]National Kidney Foundation.KDOQI clinical practice guideline for vascular access: 2019 update[J].Am J Kidney Dis, 2020, 75(4):1-164
[5]Huber, T. S . Stent Graft versus Balloon Angioplasty for Failing Dialysis-Access Grafts. [J].J Vasc Access, 2010, 362(6):494-503
[6]Aruny JE, Lewis CA, Cardella JF, et al.Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous management of the thrombosed or dysfunctional dialysis access[J].J Vasc Interv Radiol, 1999, 10(4):491-498
[7]Kelly B S, Heffelfinger S C, Whiting J F, et al.Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis[J].Kidney Int, 2002, 62(6):2272-2280
[8]Lee T, Roy-Chaudhury P.Advances and New Frontiers in the Pathophysiology of Venous Neointimal Hyperplasia and Dialysis Access Stenosis[J].Adv Chronic Kidney Dis, 2009, 16(5):329-338
[9]Nishiyama N, Komatsu T, Kuroyanagi T, et al.Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease[J]. Int J Cardiol, 2016, 222(1):113-118
[10]Schiff P B, Fant J, Horwitz S B.Promotion of microtubule assembly in vitro by taxol[J].Nature, 1979, 277(5698):665-667
[11]Scheller B, Speck U, Schmitt A, et al.Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation[J].J Am Coll Cardiol, 2003, 42(8):1415-1420
[12]Lookstein R A, Haruguchi H, Ouriel K, et al.Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas[J].N Engl J Med, 2020, 383(8):733-742
[13] Han A, Park T, Kim HJ, Min S, et al..Editor' s Choice - Paclitaxel Coated Balloon Angioplasty vs. Plain Balloon Angioplasty for Haemodialysis Arteriovenous Access Stenosis: A Systematic Review and a Time to Event Meta-Analysis of Randomised Controlled Trials.[J].Eur J Vasc Endovasc Surg., 2021, 62(4):597-609
[14]Fong KY, Zhao JJ, Tan E, et al.Drug Coated Balloons for Dysfunctional Haemodialysis Venous Access: A Patient Level Meta-Analysis of Randomised Controlled Trials. [J].Eur J Vasc Endovasc Surg., 2021, 62(4):610-621
[15] Holden A, Haruguchi H, Suemitsu K, et. IN.PACT AV Access Randomized Trial: 12-month Clinical Results Demonstrating the Sustained Treatment Effect of Drug-Coated Balloons[J].[J].J Vasc Interv Radiol, 2022, 33(8):884-894
[16]Maya I D, Oser R, Saddekni S, et al.Vascular access stenosis: Comparison of arteriovenous grafts and fistulas[J]. Am J Kidney Dis, 2004, 44(5):859-865
[17]Swedberg SH, Brown BG, Sigley R,et al.Intimal fibromuscular hyperplasia at the venous anastmosis of PTFE grafts in hemodialysis patients.Clinical, immunocytochemical, light and electron microscopic assessment[J].[J].Circulation, 1989, 80(6):1726-1736
[18]Liao MT, Lee CP, Lin TT, et al.A randomized controlled trial of drug-coated balloon angioplasty in venous anastomotic stenosis of dialysis arteriovenous grafts[J]. [J].J Vasc Surg, 2020, 71(6):1994-2003
[19]Hongsakul, Keerati, Bannangkoon, et al.Paclitaxel-Coated Balloon Angioplasty for Early Restenosis of Central Veins in Hemodialysis Patients: A Single Center Initial Experience[J].[J].Korean J Radiol, 2018, 19(3):410-416
[20]Massmann A, Fries P, Obst-Gleditsch K, et al.Paclitaxel-coated balloon angioplasty for symptomatic central vein restenosis in patients with hemodialysis fistulas[J].J Endovasc Ther, 2015, 22(1):74-79
[21] Kitrou PM, Steinke T, El Hage R, et al.Paclitaxel-Coated Balloons for the Treatment of Symptomatic Central Venous Stenosis in Vascular Access: Results From a European, Multicenter, Single-Arm Retrospective Analysis. [J].J Endovasc Ther, 2021, 28(3):442-451
[22]Bj?rkman P, Weselius EM, Kokkonen T,et al..Drug-Coated Versus Plain Balloon Angioplasty In Arteriovenous Fistulas: A Randomized, Controlled Study With 1-Year Follow-Up (The Drecorest Ii-Study). [J].Scand J Surg, 2019, 108(1):61-66
[23]Karunanithy N, Robinson E J, Ahmad F, et al.A multicenter randomized controlled trial indicates that paclitaxel-coated balloons provide no benefit during angioplasty of arteriovenous fistulas[J].Kidney Int, 2021, 100(2):447-456
[24]Liao MT, Chen MK, Hsieh MY, et al.Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials[J][J].PLoS One, 2020, 15(5):e0231463-e0231463
[25] Phang CC, Tan RY, Pang SC, et al..Paclitaxel-coated balloon in the treatment of recurrent dysfunctional arteriovenous access, real-world experience and longitudinal follow up. [J].Nephrology (Carlton), 2019, 24(12):1290-1295
[26]Tozzi M, Franchin M, Savio D, et al..Drug-coated balloon angioplasty in failing haemodialysis arteriovenous shunts: 12-month outcomes in 200 patients from the Aperto Italian registry. [J].J Vasc Access, 2019, 20(6):733-739
[27]Swedberg S H, Brown B G, Sigley R, et al.Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patientsClinical,immunocytochemical,light and electron microscopic assessment.[J].Circulation, 1989, 80(6):1726-1736
[28]Trerotola S O, Kwak A, Clark T, et al.Prospective study of balloon inflation pressures and other technical aspects of hemodialysis access angioplasty[J].J Vasc Interv Radiol, 2005, 16(12):1613-1618
[29]Kitrou PM, Spiliopoulos S, Katsanos K, et al.Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial[J].J Vasc Interv Radiol, 2015, 26(3):348-354
[30]Schorn I, Malinoff H, Anderson S, et al.The Lutonix drug-coated balloon: A novel drug delivery technology for the treatment of vascular disease[J].Adv Drug Deliv Rev, 2017, 112(5):78-87
[31]Trerotola SO, Saad TF, Roy-Chaudhury P; Lutonix AV Clinical Trial Investigators.The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis.[J].J Vasc Interv Radiol, 2020, 31(1):1-14
[32]Scheller, B.Paclitaxel Balloon Coating,a Novel Method for Prevention and Therapy of Restenosis[J].Circulation, 2004, 110(7):810-814
[33]Cremers, Bodo, Speck, et al.Drug-eluting balloon: Very short-term exposure and overlapping[J].Thromb Haemost, 2009, 101(1):201-6
[34] Hehrlein C, Richardt G, Wiemer M, et al.Description of Pantera Lux paclitaxel-releasing balloon and preliminary quantitative coronary angiography (QCA) results at six months in patients with coronary in-stent restenosis.[J].Eurolntervention, 2011, 7(5):119-124
[35] Yazdani SK, Pacheco E, Nakano M, et al..Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. [J].Catheter Cardiovasc Interv, 2014, 83(1):132-140
[36] Katsanos K, Spiliopoulos S, Kitrou P, et al.Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J].J Am Heart Assoc, 2018, 7(24):e011245-e011245
[37] Pietzsch JB, Geisler BP, Manda B, et al.. IN.PACT AV Access Trial: Economic Implications of Drug-Coated Balloon Treatment for Dysfunctional Arteriovenous Fistulas. [J].J Vasc Interv Radiol, 2022, 23(22):1051-0443
